70 related articles for article (PubMed ID: 476710)
1. Phase II trial of piperazinedione in malignant melanoma: a report by the Southeastern Cancer Study Group.
Presant CA; Bartolucci AA; Ungaro P; Oldham R
Cancer Treat Rep; 1979 Aug; 63(8):1367-9. PubMed ID: 476710
[TBL] [Abstract][Full Text] [Related]
2. Piperazinedione in patients with advanced malignant melanoma: a Southwest Oncology Group study.
Al-Sarraf M; Thigpen T; Groppe CW; Haut A; Padilla F
Cancer Treat Rep; 1978 Jul; 62(7):1101-3. PubMed ID: 356973
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
Van Amburg AL; Presant CA; Burns D
Cancer Treat Rep; 1982 Jun; 66(6):1431-3. PubMed ID: 6211234
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia.
Benjamin RS; Keating MJ; Valdivieso M; McCredie KB; Livingston RA; Burgess MA; Rodriguez V; Bodey GP; Gottlieb JA
Cancer Treat Rep; 1979 Jun; 63(6):939-43. PubMed ID: 380802
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of piperazinedione in metastatic sarcoma.
Presant CA; Bartolucci AA
Am J Clin Oncol; 1982 Apr; 5(2):185-7. PubMed ID: 7046413
[TBL] [Abstract][Full Text] [Related]
7. High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia.
Wheeler RH; Ensminger WD; Thrall JH; Anderson JL
Cancer Treat Rep; 1982 Mar; 66(3):493-8. PubMed ID: 7060037
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
9. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
11. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
[TBL] [Abstract][Full Text] [Related]
12. High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.
Buzaid AC; Murren J; Durivage HJ
Am J Clin Oncol; 1991 Jun; 14(3):203-7. PubMed ID: 1851602
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; MartÃn JA; Lardelli P
Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of diglycoaldehyde in malignant melanomas and soft tissue sarcomas.
Vosika GJ; Briscoe K; Carey RW; O'Donnell JF; Perry MC; Budman D; Richards F; Coleman M
Cancer Treat Rep; 1981; 65(9-10):823-5. PubMed ID: 7273013
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
16. Vindesine for metastatic malignant melanoma. A phase II trial.
Nelimark RA; Peterson BA; Vosika GJ; Conroy JA
Am J Clin Oncol; 1983 Oct; 6(5):561-4. PubMed ID: 6613921
[TBL] [Abstract][Full Text] [Related]
17. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
Douglass HO; MacIntyre JM; Kaufman J; Von Hoff D; Engstrom PF; Klaassen D
Cancer Treat Rep; 1985 May; 69(5):543-5. PubMed ID: 2988774
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma.
Berman E; Casper ES; Howard J; Wittes RE
Cancer Treat Rep; 1984 Apr; 68(4):679-80. PubMed ID: 6585272
[TBL] [Abstract][Full Text] [Related]
19. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Israel L; Falcoff E; Schwab D; Pouillart P
Cancer; 1986 Jul; 58(2):215-8. PubMed ID: 3719515
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study.
Schmidt H; Geertsen PF; Fode K; Rytter C; Bastholt L; von der Maase H
Melanoma Res; 2000 Feb; 10(1):66-77. PubMed ID: 10711642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]